{"protocolSection": {"identificationModule": {"nctId": "NCT04288778", "orgStudyIdInfo": {"id": "CR108749"}, "secondaryIdInfos": [{"id": "28431754DIA4032", "type": "OTHER", "domain": "Johnson & Johnson Private Limited"}], "organization": {"fullName": "Johnson & Johnson Private Limited", "class": "INDUSTRY"}, "briefTitle": "A Study to Assess Safety of Canagliflozin and Metformin Hydrochloride Combination Given as a Supplement to Diet and Exercise to Improve Blood Sugar Level in Indian Adult Participants With Diabetes", "officialTitle": "A Prospective, Multi-centric, Open-label, Single-arm, Phase 4 Study to Evaluate the Safety and Efficacy of Canagliflozin + Metformin Hydrochloride IR Fixed-dose Combination as an Adjunct to Diet and Exercise to Improve Glycemic Control in Indian Adult Patients With Type 2 Diabetes Mellitus When Treatment With Both Canagliflozin and Metformin is Appropriate"}, "statusModule": {"statusVerifiedDate": "2023-07", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2020-11-25", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2022-07-26", "type": "ACTUAL"}, "completionDateStruct": {"date": "2022-07-26", "type": "ACTUAL"}, "studyFirstSubmitDate": "2020-02-26", "studyFirstSubmitQcDate": "2020-02-26", "studyFirstPostDateStruct": {"date": "2020-02-28", "type": "ACTUAL"}, "resultsFirstSubmitDate": "2023-07-25", "resultsFirstSubmitQcDate": "2023-07-25", "resultsFirstPostDateStruct": {"date": "2023-08-18", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2023-07-25", "lastUpdatePostDateStruct": {"date": "2023-08-18", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Johnson & Johnson Private Limited", "class": "INDUSTRY"}}, "oversightModule": {"isFdaRegulatedDrug": true, "isFdaRegulatedDevice": false, "isUsExport": true}, "descriptionModule": {"briefSummary": "The purpose of this study is to assess safety of canagliflozin + metformin hydrochloride immediate Release (IR) fixed-dose combination."}, "conditionsModule": {"conditions": ["Diabetes Mellitus"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "NA", "interventionModel": "SINGLE_GROUP", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 276, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Canagliflozin + Metformin Hydrochloride Immediate Release (IR)", "type": "EXPERIMENTAL", "description": "Participants will receive canagliflozin + metformin hydrochloride IR fixed-dose combination, 50 milligram (mg) + 500 mg or 50 mg + 1000 mg, will be provided as tablets for oral administration.", "interventionNames": ["Drug: Canagliflozin + Metformin hydrochloride (Fixed Dose Combination)"]}], "interventions": [{"type": "DRUG", "name": "Canagliflozin + Metformin hydrochloride (Fixed Dose Combination)", "description": "Participants will receive canagliflozin + metformin hydrochloride IR fixed-dose combination, 50 milligram (mg) + 500 mg or 50 mg + 1000 mg, will be provided as tablets for oral administration. The study Treatment duration will be of 24 weeks.", "armGroupLabels": ["Canagliflozin + Metformin Hydrochloride Immediate Release (IR)"], "otherNames": ["JNJ-28431754"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Percentage of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)", "description": "An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious adverse event (SAE) was any untoward medical occurrence that at any dose resulted in death, was life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a suspected transmission of any infectious agent via a medicinal product. TEAEs were defined as events that started on or after the study medication start date and time.", "timeFrame": "Baseline (Day 1) up to 24 weeks"}, {"measure": "Percentage of Participants With Unexpected Adverse Events (AEs)", "description": "An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An adverse event was considered unexpected if the nature or severity was not consistent with the applicable product reference safety information.", "timeFrame": "Baseline (Day 1) up to 24 weeks"}, {"measure": "Percentage of Participants With Adverse Drug Reactions (ADRs)", "description": "ADRs were defined as the treatment related TEAEs. Treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. TEAEs were defined as events that started on or after the study medication start date and time.", "timeFrame": "Baseline (Day 1) up to 24 weeks"}], "secondaryOutcomes": [{"measure": "Percent Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Weeks 12 and 24", "description": "Percent change from baseline in HbA1c at Weeks 12 and 24 was reported.", "timeFrame": "Baseline, Weeks 12 and 24"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Participant willing to adhere to diet and exercise regimen as recommended by the investigator\n* Type 2 diabetes mellitus (T2DM) with inadequate glycemic control on diet and exercise, who in investigator's opinion are eligible to receive study drug as per prescribing information along with standard care for management of T2DM\n* Women must be postmenopausal, defined as greater than (\\>) 45 years of age with amenorrhea for at least 18 months, or \\> 45 years of age with amenorrhea for at least 6 months and less than (\\<) 18 months and a serum follicle stimulating hormone (FSH) level \\> 40 International Units Per Liter (IU/L), or surgically sterile (have had a hysterectomy or bilateral oophorectomy, tubal occlusion), or otherwise be incapable of pregnancy, or sexually active and practicing a highly effective method of birth control, including hormonal prescription oral contraceptives, contraceptive injections, contraceptive patch, tubal ligation, intrauterine device, double-barrier method (example, condoms, diaphragm, or cervical cap with spermicidal foam, cream, or gel), or male partner sterilization, and consistent with local regulations regarding use of birth control methods for participant participating in clinical studies, for the duration of their participation in the study, or not sexually active\n* Women of childbearing potential, regardless of age must have a negative serum beta-human chorionic gonadotropin (beta-hCG) pregnancy test at screening and negative UPT at baseline (predose, Day 1)\n* Treatment naive participants or participants on stable antihyperglycemic agent (AHA) therapy (for at least 12 weeks before screening) and have a screening visit Glycosylated Haemoglobin (HbA1c) of greater than or equal to (\\>=) 7.0 percent (%) and less than or equal to (\\<=) 10.0 %\n\nExclusion Criteria:\n\n* History of liver or renal insufficiency (estimated creatinine clearance below 45 milliliter per minute \\[mL/min\\]); significant cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances\n* Known allergies, hypersensitivity, or intolerance to Canagliflozin, Metformin or Canagliflozin + metformin hydrochloride immediate release (IR) Fixed Dose combination (FDC) or its excipients\n* Use of any other sodium glucose cotransporter 2 (SGLT2) inhibitor within 12 weeks before the screening visit\n* If female, the participant is pregnant or lactating or intending to become pregnant before, during, or within 30 days after last dose of study medication; or intending to donate ova during such time period\n* History of diabetic ketoacidosis, type 1 diabetes mellitus (T1DM), pancreas or beta-cell transplantation, or diabetes secondary to pancreatitis or pancreatectomy", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "65 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Johnson & Johnson Private Limited Clinical Trial", "affiliation": "Johnson & Johnson Private Limited", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Lifecare Hospital and Research Centre", "city": "Bengaluru", "zip": "560092", "country": "India", "geoPoint": {"lat": 12.97194, "lon": 77.59369}}, {"facility": "Post Graduate Institute of Medical Education & Research (PGIMER)", "city": "Chandigarh", "zip": "160012", "country": "India", "geoPoint": {"lat": 30.73629, "lon": 76.7884}}, {"facility": "Kovai Diabetes Specialty Centre & Hospital", "city": "Coimbatore", "zip": "641 009", "country": "India", "geoPoint": {"lat": 11.00555, "lon": 76.96612}}, {"facility": "Excelcare Hospitals (A unit of Asclepius Hospitals and Health Care Pvt. Ltd.)", "city": "Guwahati", "zip": "781033", "country": "India", "geoPoint": {"lat": 26.1844, "lon": 91.7458}}, {"facility": "Thumbay Hospital New life / Endocrinology", "city": "Hyderabad", "zip": "500024", "country": "India", "geoPoint": {"lat": 17.38405, "lon": 78.45636}}, {"facility": "Fortis Hospital", "city": "Mohali", "zip": "160062", "country": "India", "geoPoint": {"lat": 30.67995, "lon": 76.72211}}, {"facility": "Jehangir Clinical Development Center Pvt Ltd", "city": "Pune", "zip": "411001", "country": "India", "geoPoint": {"lat": 18.51957, "lon": 73.85535}}, {"facility": "Chellaram Diabetes Institute", "city": "Pune", "zip": "411021", "country": "India", "geoPoint": {"lat": 18.51957, "lon": 73.85535}}, {"facility": "Nirmal Hospital Pvt. Ltd.", "city": "Surat", "zip": "395002", "country": "India", "geoPoint": {"lat": 21.19594, "lon": 72.83023}}, {"facility": "Jothydev's Diabetes Research Centre", "city": "Trivandrum", "zip": "695032", "country": "India", "geoPoint": {"lat": 8.4855, "lon": 76.94924}}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \\& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu", "url": "https://www.janssen.com/clinical-trials/transparency"}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Canagliflozin + Metformin Hydrochloride FDC", "description": "Participants received either (canagliflozin 50 milligram \\[mg\\] + metformin hydrochloride 500 mg) or (canagliflozin 50 mg + metformin hydrochloride 1000 mg) immediate release (IR) fixed-dose combination (FDC) tablets twice daily (BD) up to Week 24."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "276"}]}, {"type": "Treated", "achievements": [{"groupId": "FG000", "numSubjects": "274"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "265"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "11"}]}], "dropWithdraws": [{"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "2"}]}, {"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "5"}]}, {"type": "Non-Compliance With Study Drug", "reasons": [{"groupId": "FG000", "numSubjects": "1"}]}, {"type": "Other", "reasons": [{"groupId": "FG000", "numSubjects": "1"}]}, {"type": "Started but not treated", "reasons": [{"groupId": "FG000", "numSubjects": "2"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "Safety analysis set included all participants who had taken at least 1 dose of study treatment.", "groups": [{"id": "BG000", "title": "Canagliflozin + Metformin Hydrochloride FDC", "description": "Participants received either (canagliflozin 50 milligram \\[mg\\] + metformin hydrochloride 500 mg) or (canagliflozin 50 mg + metformin hydrochloride 1000 mg) immediate release (IR) fixed-dose combination (FDC) tablets twice daily (BD) up to Week 24."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "274"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "52.1", "spread": "8.34"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "106"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "168"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"title": "Indian", "categories": [{"measurements": [{"groupId": "BG000", "value": "274"}]}]}]}, {"title": "Region of Enrollment", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"title": "India", "categories": [{"measurements": [{"groupId": "BG000", "value": "274"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Percentage of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)", "description": "An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious adverse event (SAE) was any untoward medical occurrence that at any dose resulted in death, was life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a suspected transmission of any infectious agent via a medicinal product. TEAEs were defined as events that started on or after the study medication start date and time.", "populationDescription": "Safety analysis set included all participants who had taken at least 1 dose of study treatment.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "Baseline (Day 1) up to 24 weeks", "groups": [{"id": "OG000", "title": "Canagliflozin + Metformin Hydrochloride FDC", "description": "Participants received either (canagliflozin 50 milligram \\[mg\\] + metformin hydrochloride 500 mg) or (canagliflozin 50 mg + metformin hydrochloride 1000 mg) immediate release (IR) fixed-dose combination (FDC) tablets twice daily (BD) up to Week 24."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "274"}]}], "classes": [{"title": "TEAEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "41.6"}]}]}, {"title": "TESAEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.1"}]}]}]}, {"type": "PRIMARY", "title": "Percentage of Participants With Unexpected Adverse Events (AEs)", "description": "An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An adverse event was considered unexpected if the nature or severity was not consistent with the applicable product reference safety information.", "populationDescription": "Safety analysis set included all participants who had taken at least 1 dose of study treatment.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "Baseline (Day 1) up to 24 weeks", "groups": [{"id": "OG000", "title": "Canagliflozin + Metformin Hydrochloride FDC", "description": "Participants received either (canagliflozin 50 milligram \\[mg\\] + metformin hydrochloride 500 mg) or (canagliflozin 50 mg + metformin hydrochloride 1000 mg) immediate release (IR) fixed-dose combination (FDC) tablets twice daily (BD) up to Week 24."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "274"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Percent Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Weeks 12 and 24", "description": "Percent change from baseline in HbA1c at Weeks 12 and 24 was reported.", "populationDescription": "Efficacy analysis set included all participants who had taken at least 1 dose of study treatment and had both baseline and at least 1 post-baseline efficacy assessment. Here, 'N' (number of participants analyzed) signifies number of participants evaluable for this outcome measure and 'n' (number analyzed) represents number of participants evaluable at the specified timepoints.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percent change", "timeFrame": "Baseline, Weeks 12 and 24", "groups": [{"id": "OG000", "title": "Canagliflozin + Metformin Hydrochloride FDC", "description": "Participants received either (canagliflozin 50 milligram \\[mg\\] + metformin hydrochloride 500 mg) or (canagliflozin 50 mg + metformin hydrochloride 1000 mg) immediate release (IR) fixed-dose combination (FDC) tablets twice daily (BD) up to Week 24."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "265"}]}], "classes": [{"title": "Percent change at Week 12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "264"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.918", "spread": "1.1348"}]}]}, {"title": "Percent change at Week 24", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "265"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.926", "spread": "1.3054"}]}]}]}, {"type": "PRIMARY", "title": "Percentage of Participants With Adverse Drug Reactions (ADRs)", "description": "ADRs were defined as the treatment related TEAEs. Treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. TEAEs were defined as events that started on or after the study medication start date and time.", "populationDescription": "Safety analysis set included all participants who had taken at least 1 dose of study treatment.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "Baseline (Day 1) up to 24 weeks", "groups": [{"id": "OG000", "title": "Canagliflozin + Metformin Hydrochloride FDC", "description": "Participants received either (canagliflozin 50 milligram \\[mg\\] + metformin hydrochloride 500 mg) or (canagliflozin 50 mg + metformin hydrochloride 1000 mg) immediate release (IR) fixed-dose combination (FDC) tablets twice daily (BD) up to Week 24."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "274"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "10.6"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "timeFrame": "Baseline (Day 1) up to end of study (28 weeks)", "description": "Safety analysis set included all participants who had taken at least 1 dose of study treatment.", "eventGroups": [{"id": "EG000", "title": "Canagliflozin + Metformin Hydrochloride FDC", "description": "Participants received either (canagliflozin 50 milligram \\[mg\\] + metformin hydrochloride 500 mg) or (canagliflozin 50 mg + metformin hydrochloride 1000 mg) immediate release (IR) fixed-dose combination (FDC) tablets twice daily (BD) up to Week 24.", "deathsNumAffected": 0, "deathsNumAtRisk": 274, "seriousNumAffected": 3, "seriousNumAtRisk": 274, "otherNumAffected": 114, "otherNumAtRisk": 274}], "seriousEvents": [{"term": "COVID-19", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA Version 25.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 274}]}, {"term": "Urinary Tract Infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA Version 25.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 274}]}, {"term": "Diabetic Ketoacidosis", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA Version 25.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 274}]}, {"term": "Prostatomegaly", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA Version 25.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 274}]}], "otherEvents": [{"term": "Anaemia", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA Version 25.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 274}]}, {"term": "Lymphopenia", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA Version 25.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 274}]}, {"term": "Palpitations", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA Version 25.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 274}]}, {"term": "Sinus Bradycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA Version 25.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 274}]}, {"term": "Sinus Tachycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA Version 25.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 274}]}, {"term": "Hydrocele", "organSystem": "Congenital, familial and genetic disorders", "sourceVocabulary": "MedDRA Version 25.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 274}]}, {"term": "Cataract", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA Version 25.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 274}]}, {"term": "Diabetic Retinal Oedema", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA Version 25.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 274}]}, {"term": "Constipation", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA Version 25.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 274}]}, {"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA Version 25.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 274}]}, {"term": "Dyspepsia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA Version 25.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 274}]}, {"term": "Frequent Bowel Movements", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA Version 25.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 274}]}, {"term": "Gastritis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA Version 25.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 274}]}, {"term": "Hyperchlorhydria", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA Version 25.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 274}]}, {"term": "Stomatitis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA Version 25.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 274}]}, {"term": "Toothache", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA Version 25.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 274}]}, {"term": "Asthenia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA Version 25.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 274}]}, {"term": "Chest Pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA Version 25.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 274}]}, {"term": "Fatigue", "organSystem": "General disorders", "sourceVocabulary": "MedDRA Version 25.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 274}]}, {"term": "Pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA Version 25.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 274}]}, {"term": "Pyrexia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA Version 25.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 13, "numAtRisk": 274}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA Version 25.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 274}]}, {"term": "COVID-19", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA Version 25.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 274}]}, {"term": "Carbuncle", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA Version 25.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 274}]}, {"term": "Dengue Fever", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA Version 25.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 274}]}, {"term": "Dysentery", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA Version 25.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 274}]}, {"term": "Fungal Infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA Version 25.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 274}]}, {"term": "Fungal Skin Infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA Version 25.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 274}]}, {"term": "Gastroenteritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA Version 25.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 274}]}, {"term": "Genital Infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA Version 25.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 9, "numAtRisk": 274}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA Version 25.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 274}]}, {"term": "Orchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA Version 25.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 274}]}, {"term": "Tinea Cruris", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA Version 25.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 274}]}, {"term": "Urinary Tract Infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA Version 25.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 7, "numAtRisk": 274}]}, {"term": "Vaginal Infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA Version 25.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 274}]}, {"term": "Vulvovaginitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA Version 25.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 274}]}, {"term": "Limb Injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA Version 25.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 274}]}, {"term": "Albumin Urine Present", "organSystem": "Investigations", "sourceVocabulary": "MedDRA Version 25.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 274}]}, {"term": "Blood Creatinine Increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA Version 25.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 274}]}, {"term": "Blood Pressure Increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA Version 25.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 274}]}, {"term": "Blood Triglycerides Increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA Version 25.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 274}]}, {"term": "Urine Albumin/Creatinine Ratio Increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA Version 25.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 274}]}, {"term": "Weight Decreased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA Version 25.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 274}]}, {"term": "Decreased Appetite", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA Version 25.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 274}]}, {"term": "Diabetes Mellitus Inadequate Control", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA Version 25.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 274}]}, {"term": "Diabetic Ketoacidosis", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA Version 25.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 274}]}, {"term": "Dyslipidaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA Version 25.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 13, "numAtRisk": 274}]}, {"term": "Hyperlipidaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA Version 25.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 274}]}, {"term": "Hypertriglyceridaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA Version 25.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 274}]}, {"term": "Hypoglycaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA Version 25.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 9, "numAtRisk": 274}]}, {"term": "Type 2 Diabetes Mellitus", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA Version 25.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 274}]}, {"term": "Vitamin B12 Deficiency", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA Version 25.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 274}]}, {"term": "Arthralgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA Version 25.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 274}]}, {"term": "Back Pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA Version 25.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 274}]}, {"term": "Fibromyalgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA Version 25.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 274}]}, {"term": "Joint Swelling", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA Version 25.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 274}]}, {"term": "Muscle Spasms", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA Version 25.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 274}]}, {"term": "Myalgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA Version 25.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 274}]}, {"term": "Neck Pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA Version 25.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 274}]}, {"term": "Pain in Extremity", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA Version 25.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 274}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA Version 25.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 274}]}, {"term": "Dizziness Exertional", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA Version 25.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 274}]}, {"term": "Head Discomfort", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA Version 25.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 274}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA Version 25.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 274}]}, {"term": "Hypoaesthesia", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA Version 25.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 274}]}, {"term": "Lethargy", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA Version 25.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 274}]}, {"term": "Paraesthesia", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA Version 25.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 274}]}, {"term": "Anxiety", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA Version 25.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 274}]}, {"term": "Albuminuria", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA Version 25.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 274}]}, {"term": "Dysuria", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA Version 25.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 274}]}, {"term": "Microalbuminuria", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA Version 25.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 274}]}, {"term": "Micturition Urgency", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA Version 25.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 274}]}, {"term": "Nephrolithiasis", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA Version 25.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 274}]}, {"term": "Proteinuria", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA Version 25.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 274}]}, {"term": "Adenomyosis", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA Version 25.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 274}]}, {"term": "Balanoposthitis", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA Version 25.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 274}]}, {"term": "Prostatomegaly", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA Version 25.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 274}]}, {"term": "Pruritus Genital", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA Version 25.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 274}]}, {"term": "Smegma Accumulation", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA Version 25.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 274}]}, {"term": "Vulvovaginal Pruritus", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA Version 25.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 274}]}, {"term": "Dyspnoea Exertional", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA Version 25.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 274}]}, {"term": "Nasal Pruritus", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA Version 25.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 274}]}, {"term": "Upper Respiratory Tract Congestion", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA Version 25.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 274}]}, {"term": "Dermatitis Allergic", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA Version 25.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 274}]}, {"term": "Hyperhidrosis", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA Version 25.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 274}]}, {"term": "Pruritus", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA Version 25.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 274}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA Version 25.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 274}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days."}, "pointOfContact": {"title": "Medical Advisor", "organization": "Janssen Research & Development, LLC", "email": "ClinicalTrialDisclosure@its.jnj.com", "phone": "844-434-4210"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot", "hasProtocol": true, "hasSap": false, "hasIcf": false, "label": "Study Protocol", "date": "2021-02-04", "uploadDate": "2023-07-25T05:10", "filename": "Prot_000.pdf", "size": 2744167}, {"typeAbbrev": "SAP", "hasProtocol": false, "hasSap": true, "hasIcf": false, "label": "Statistical Analysis Plan", "date": "2022-03-10", "uploadDate": "2023-07-25T05:11", "filename": "SAP_001.pdf", "size": 536931}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000003920", "term": "Diabetes Mellitus"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "relevance": "LOW"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}, {"id": "D000068896", "term": "Canagliflozin"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000077203", "term": "Sodium-Glucose Transporter 2 Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M11667", "name": "Metformin", "asFound": "Facial", "relevance": "HIGH"}, {"id": "M331", "name": "Canagliflozin", "asFound": "Nasopharyngeal", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M1691", "name": "Sodium-Glucose Transporter 2 Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}